Navigation Links
Outlook improves for patients with non-Hodgkin lymphoma over past decade
Date:3/10/2008

Five- and 10-year survival rates for patients with non-Hodgkin lymphoma appear to have increased from the 1990s to the early 21st century, according to a report in the March 10 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Non-Hodgkin lymphoma includes several cancers of the immune system that occur in approximately 20.4 of every 100,000 individuals, according to background information in the article. Treatment for the condition has evolved rapidly in recent years.

Dianne Pulte, M.D., of the German Cancer Research Center, Heidelberg, and colleagues analyzed data from the Surveillance, Epidemiology and End Results (SEER) Program of the U.S. National Cancer Institute. Survival rates were calculated based on two-year time periods between 1990 and 2004 within which patients were diagnosed with non-Hodgkin lymphoma, as well as by age group (15 to 44, 45 to 54, 55 to 64, 65 to 74 and 75 years or older), sex, race, tumor location (i.e. whether the disease was nodal [in the lymph nodes] or extranodal [in a site other than the lymph nodes]) and histologic subtype (to classify tumors as high-grade or low-grade).

Overall, five-year relative survival increased from 50.4 percent to 66.8 percent, and 10-year relative survival increased from 39.4 percent to 56.3 percent between 1990 to 1992 and 2002 to 2004, the authors write. Improvements were most pronounced in patients younger than 45 years (plus 26.8 and plus 27.1 percentage points for five- and 10-year survival, respectively), but improvements were seen in all age groups, in both sexes, in both nodal and extranodal disease and in both low-grade and high-grade disease. Improvements in prognosis were less in black patients than in white patients, especially in younger black patients.

Two factors may explain these improvements, the authors note. One is advances in therapy that have occurred between 1990 and 2004, particularly the introduction of antibody therapy for non-Hodgkin lymphoma, they write. Treatment with antibody therapy and chemotherapy has extended life expectancy in many cases, but whether and how often this extension represents a true cure is still unknown. In addition, improvements in the treatment of HIV have reduced the occurrence of HIV-related non-Hodgkin lymphomas and also made them easier to treat.

Our estimates of long-term survival in patients with non-Hodgkin lymphoma obtained by the period analysis method for the 2002 to 2004 period are much higher than previously available survival estimates, which mostly pertain to patients diagnosed in the 1990s, the authors conclude. Timely disclosure of the improvements in survival achieved in patients, clinicians, researchers and the public is essential.


'/>"/>

Contact: Hermann Brenner
h.brenner@dkfz-heidelberg.de
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Gentiva(R) Health Services Announces Fourth Quarter and Fiscal 2007 Results, and Raises 2008 Outlook
2. Legislative and Regulatory Outlook - 2009 and Beyond for Pharma, Biotech Players
3. Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10.8% and 9.2%, Respectively; 2007 Earnings Per Share Beat Outlook
4. Cardinal Health Reports Second Quarter Results, Revises EPS Outlook
5. Matrixx Initiatives, Inc. Updates 2007/2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook
6. Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook
7. Medco CEO Reiterates Guidance, Positive Outlook for 2008
8. Private Equitys Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference
9. WellPoint Highlights 2007 Accomplishments and Strong 2008 Outlook at Annual Investor Meeting
10. MedCath Corporation Reports Fourth Quarter Earnings and Outlook for Fiscal 2008
11. Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... ... Grass pollen is the main cause of hay fever in the United States, with an ... runs from May to July each year; with the worst time for sufferers being June ... balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its ... from high school and college students who have participated in the program every summer. ... YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear announced today ... normally at $29.97; for the remaining days of March, the price will be only ... a special price of just $10 (regular retail price $19.97). , The special promotional ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, ... Stores in two southeastern states. Ingredients in HeartBoost, an over the counter heart ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based ... into the challenges employers face in trying to balance both short-term and long-term ... programs? Adding to the growing complexity, companies are finding that the short-term ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  The leader in ... that Drs. Sam Daher , Manal Ibrahim ... and David Couchat will be the featured microlecture presenters ... upcoming American Association of Orthodontists (AAO) Annual Session, April ... attend the microlectures beginning daily at 11:20 a.m. On ...
(Date:3/29/2017)... Texas , March 29, 2017  Maxor National ... today announced that it has named Leah Bailey ... for all divisions of the company. With ... including the previous 8 years focused on health care, ... During her tenure at Prime, Bailey advised the PBM, ...
(Date:3/29/2017)... 2017  Designers of primary cell wearable medical and ... 50% and extend battery life with the MAX20310 ultra-low ... (PMIC) from Maxim Integrated Products, Inc. (NASDAQ: ... voltage of just 0.7V for new high-energy density battery ... well as the more common Alkaline battery architecture. With ...
Breaking Medicine Technology: